Venomics AI
Venomics AI operates an AI-driven drug discovery engine that decodes venom-derived peptides from over 20 million bioactive toxin sequences to develop novel therapeutics. The platform integrates high-throughput electrophysiology, machine learning, and automated synthesis to target more than 100 disease-relevant proteins, including antimicrobial, pain, and metabolic pathways. Its pipeline produces data-rich candidate dossiers for pharmaceutical partners to advance into preclinical development.
- Drug Discovery & Therapeutics
- Biotechnology
- Artificial Intelligence
- Healthcare Technology
Funding
Raised to date
$2.7MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
across 1 round
$2.7M · Pre-Seed
Announced Nov 2026 · from article date
Disclosed cumulative: $2.7M
Founders
Founder details are not available yet.
Product
Problem
Traditional drug discovery pipelines often struggle to find novel, highly selective molecules, leading to long development timelines and high failure rates, especially for emerging challenges such as antimicrobial resistance and metabolic disorders.
Solution
Venomics AI combines venom biology, high‑throughput electrophysiology, and artificial‑intelligence‑driven analysis to rapidly decode and screen millions of bioactive peptides from diverse venom sources. The platform automates the progression from venom extraction through electrophysiological screening, AI‑based hit identification, and chemical synthesis, delivering candidate therapeutics for more than 100 disease‑relevant targets. By leveraging the evolutionary optimization of venom peptides, Venomics AI generates molecules with inherent potency and selectivity, accelerating the creation of new antibiotics, non‑opioid analgesics, and metabolic disease agents. The end‑to‑end pipeline produces data-rich candidate dossiers that can be handed off to partner pharmaceutical companies for preclinical and clinical development.
Target Audience
Primary customers are pharmaceutical and biotechnology companies seeking novel, high‑affinity biologics for antimicrobial, pain‑management, and metabolic indications, as well as contract research organizations that require rapid hit generation and candidate optimization.
Features
- Access to a library of over 20 million unique venom‑derived peptides spanning a broad phylogenetic spectrum, with 5.6M transcripts and 5.6M proteins decoded from venom-gland transcriptomics and proteomics
- High‑throughput electrophysiology platform that measures peptide activity across multiple target classes in a single run, including ion channel and receptor pharmacology validation
- AI models that prioritize hits for potency, selectivity, and developability, reducing manual triage time and linking peptide structure to functional outcomes
- Automated synthesis workflow that converts selected peptide sequences into scalable drug candidates
- Integrated analytics enabling rational engineering of antimicrobial, analgesic, and metabolic agents, with capability to target more than 100 disease‑relevant proteins
- Six-stage discovery engine spanning venom evolution, decoding, screening, AI modeling, engineering, and drug lead advancement